ALXO
NASDAQ
US
ALX Oncology Holdings Inc. - Common Stock
$1.97
▼ $-0.01
(-0.51%)
Vol 415K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$61.3M
ROE
-138.9%
Margin
-753.6%
D/E
26.56
Beta
0.49
52W
$0–$2
Wall Street Consensus
13 analysts · Apr 20263
Strong Buy
8
Buy
2
Hold
0
Sell
0
Strong Sell
84.6%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 25.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.37 | $-0.37 | $0.00 |
| Sep 2025 | $-0.37 | $-0.41 | $-0.04 |
| Jun 2025 | $-0.46 | $-0.43 | +$0.03 |
| Mar 2025 | $-0.47 | $-0.58 | $-0.11 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net Income | — | -$29.2M | -$30.8M | -$25.9M | -$22.1M | -$22.8M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -115.7% | -115.7% | -115.7% | -115.7% | -138.9% | -138.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -753.5% | -753.5% | -753.5% | -753.5% | -753.5% |
| Gross Margin | — | 9.0% | 9.0% | 9.0% | 9.0% | 9.0% |
| D/E Ratio | 18.99 | 18.99 | 18.99 | 18.99 | 26.56 | 26.56 |
| Current Ratio | 4.52 | 4.52 | 4.52 | 4.52 | 2.40 | 2.40 |
Key Ratios
ROA (TTM)
-96.7%
P/S (TTM)
16.74
P/B
0.8
EPS (TTM)
$-2.01
CF/Share
$-3.54
52W High
$2.27
52W Low
$0.40
$0.40
52-Week Range
$2.27
Financial Health
Free Cash Flow
-$19.0M
Net Debt
-$6.6M
Cash
$16.4M
Total Debt
$9.7M
As of Dec 31, 2025
How does ALXO compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ALXO valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
16.7
▲
30%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.8
▼
69%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ALXO profitability vs Biotechnology peers
ROE
-138.9%
▼
106%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-753.6%
▼
163%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
9.0%
▼
89%
below
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-96.7%
▼
107%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
ALXO financial health vs Biotechnology peers
D/E ratio
26.6
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.4
▼
46%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.5
▼
49%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ALXO fundamentals radar
ALXO
Peer median
Industry
ALXO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ALXO vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
LETTMANN JASON
Chief Executive Officer · Mar 19
12311 shs
PINTO SHELLY
Officer · Mar 19
903 shs
PINTO SHELLY
Officer · Feb 18
565 shs
GOODMAN COREY S
Director and Beneficial Owner… · Feb 02
3184713 shs
PINTO SHELLY
Officer · Jan 06
3925 shs
Last 90 days
Top Holders
Top 5: 15.45%venBio Partners LLC
7.37%
$19.8M
Redmile Group, LLC
2.48%
$6.7M
Millennium Management Llc
2.43%
$6.5M
Almitas Capital LLC
1.93%
$5.2M
Vanguard Group Inc
1.24%
$3.3M
As of Dec 31, 2025
Latest News
No related news yet